Top 5 Takeaways

1. PRIORIX, a new MMR (Measles, Mumps, and Rubella) vaccine, has been licensed and recommended by the Advisory Committee on Immunization Practices (ACIP) in the United States as an additional option alongside the existing M-M-R II vaccine.
2. The ACIP’s recommendation is based on a systematic review of PRIORIX’s safety and immunogenicity, indicating its noninferiority to M-M-R II.
3. Both PRIORIX and M-M-R II are considered interchangeable for all recommended MMR vaccinations, including off-label uses.
4. The addition of PRIORIX aims to diversify the U.S. vaccine supply and maintain high vaccination coverage, crucial for preventing measles, mumps, and rubella, as well as their associated complications.
5. PRIORIX, like M-M-R II, is recommended for routine and catch-up vaccination in various age groups, with specific guidelines for dosage and administration.

Original Article Author and Citation

Corresponding Author

Elisabeth Krow-Lucal,

Suggested Citation

Krow-Lucal E, Marin M, Shepersky L, Bahta L, Loehr J, Dooling K. Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1465–1470. DOI: 10.15585/mmwr.mm7146a1.


The ACIP has recommended PRIORIX, licensed in June 2022, as an additional MMR vaccine option in the U.S. This decision follows a comprehensive review of PRIORIX’s safety and immunogenicity, showing it to be comparable to the long-used M-M-R II vaccine. Both vaccines are fully interchangeable for all indications where MMR vaccination is recommended.


The ACIP’s decision was based on a systematic review of literature and data from clinical trials and observational studies. These studies evaluated safety, immunogenicity, and adverse events associated with PRIORIX at various potencies.


The introduction of PRIORIX is significant for public health, offering an additional vaccine option and strengthening the U.S. vaccine supply against measles, mumps, and rubella. High vaccination coverage has been pivotal in eliminating these diseases in the U.S., and the ACIP’s recommendation emphasizes the importance of maintaining this coverage.


PRIORIX is now a recommended option for MMR vaccination in the United States. Its safety profile, efficacy, and interchangeability with M-M-R II make it a valuable addition to public health efforts in controlling measles, mumps, and rubella.


This has been your booster shot of MMWR Info! Please check back for more MMWR, Public Health, and Programming Tutorial content daily.


Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>